Education
About Us
Working with TipRanks
Follow Us
Mediwound (MDWD)
NASDAQ:MDWD
MDWD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$12.78 - $24.00
Previous CloseN/A
Volume29.05K
Average Volume (3M)72.69K
Market Cap
$225.56M
Enterprise ValueN/A
Total Cash (Recent Filing)$9.15M
Total Debt (Recent Filing)$6.51M
Price to Earnings (P/E)―
Beta0.97
Next Earnings
Aug 12, 2025EPS Estimate
-0.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding10,807,726
10 Day Avg. Volume105,713
30 Day Avg. Volume72,694
Financial Highlights & Ratios
PEG Ratio0.97
Price to Book (P/B)5.52
Price to Sales (P/S)0.00
P/FCF Ratio-9.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$28.67Price Target Upside40.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Mediwound News
Bulls Say, Bears Say
Bulls Say
FundingMediWound received €16.5 million in funding from the European Innovation Council to accelerate the development of EscharEx.
Market OpportunityEscharEx is being developed for enzymatic debridement of chronic wounds, representing a potential $2.5 billion market opportunity.
Product RolloutNexoBrid's US rollout by partner Vericel continues to build momentum, as Vericel reported revenue increases for the product.
Bears Say
Guidance AdjustmentNexoBrid guidance tightened towards lower end, reflecting adjusted timelines for EU approval of the manufacturing facility.
Revenue PerformanceRevenue in 1Q totaled $4.0 million, down from $5.0 million and below the Street's $5.2 million expectation.
Supply LimitationsGlobal demand for NexoBrid currently exceeds MDWD's manufacturing capacity, limiting sales despite high demand.
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
1.96% Mutual Funds
24.81% Other Institutional Investors
68.78% Public Companies and Individual Investors
MDWD FAQ
What was Mediwound’s price range in the past 12 months?
Mediwound lowest stock price was $12.78 and its highest was $24.00 in the past 12 months.
What is Mediwound’s market cap?
Mediwound’s market cap is $225.56M.
When is Mediwound’s upcoming earnings report date?
Mediwound’s upcoming earnings report date is Aug 12, 2025 which is in 81 days.
How were Mediwound’s earnings last quarter?
Mediwound released its earnings results on May 21, 2025. The company reported -$0.07 earnings per share for the quarter, beating the consensus estimate of -$0.662 by $0.592.
Is Mediwound overvalued?
According to Wall Street analysts Mediwound’s price is currently Undervalued.
Does Mediwound pay dividends?
Mediwound does not currently pay dividends.
What is Mediwound’s EPS estimate?
Mediwound’s EPS estimate is -0.65.
How many shares outstanding does Mediwound have?
Mediwound has 10,807,726 shares outstanding.
What happened to Mediwound’s price movement after its last earnings report?
Mediwound reported an EPS of -$0.07 in its last earnings report, beating expectations of -$0.662. Following the earnings report the stock price went down -4.696%.
Which hedge fund is a major shareholder of Mediwound?
Currently, no hedge funds are holding shares in MDWD
Mediwound Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$28.67 (40.95% Upside)
$28.67 (40.95% Upside)
Blogger Sentiment
Bullish
MDWD Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 6.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 5.7%
Last 30 Days ▼ 13.5%
Last 30 Days ▼ 13.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
15.77%
12-Months-Change
Fundamentals
Return on Equity
-77.92%
Trailing 12-Months
Asset Growth
10.64%
Trailing 12-Months
Company Description
Mediwound
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
MDWD Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed outlook for MediWound. While there are significant advancements in clinical trials and strategic collaborations, financial metrics reveal challenges with declining revenue and increased losses. However, the strong growth in NexoBrid's adoption and the strategic initiatives for EscharEx show promise for future performance.Read More>MDWD Stock 12 Month Forecast
Average Price Target
$28.67
▲( 40.95% Upside)